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Background: Chronic Kidney Disease (CKD) is associated with an increased risk for
stent thrombosis and adverse events following percutaneous coronary intervention
(PCI). High platelet reactivity (HPR) is also an independent correlate of thrombotic
events post PCI. Although CKD modulates platelet function, the impact of CKD on
HPR remains controversial, and whether or not HPR confers a differential risk for
MACE between CKD and non-CKD patients is unknown.
Methods: We performed a post-hoc analysis of the ADAPT-DES registry, which
included 8,583 patients (8,449 of whom had baseline serum creatinine measures)
undergoing PCI with successful DES placement. All patients underwent platelet
function testing using the VerifyNow assay. HPR was deﬁned as platelet reactivity
units (PRU) 208. CKD was deﬁned as a creatinine clearance <60 mL/min. We
compared the frequency and impact of HPR on MACE between CKD and non-CKD
patients.
Results: Patients with CKD (n¼1,395; 16.5%) were older and more often female and
diabetic, and had a lower ejection fraction compared to their non-CKD counterparts
(n¼7,054). Unadjusted HPR prevalence was higher among those with vs. without
CKD (48.9% vs. 41.5%, P<0.001). However, after multivariable adjustment this
association was attenuated and no longer signiﬁcant. While 1-year MACE rates were
higher among those with vs. without CKD (6.6% vs. 3.6%, P<0.001), the adverse and
incremental impact of HPR on MACE was uniform across CKD strata (pint ¼ NS for
all endpoints, Table 1).
Conclusions: While HPR is more common among those with CKD, this association
appears largely attributable to confounding risk factors that are more prevalent in these
patients. The incremental impact of HPR on MACE is similar among those with and
without CKD.Table 1. Adjudicated Events to 1-Year
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Stent
thrombosis
(deﬁnite/
probable)
1.8% (12) 0.6% (4) 3.18 [1.03,
9.87]
1.2% (33) 0.5% (20) 2.34 [1.34,
4.08]
Cardiac
death or MI
7.3% (48) 5.6% (39) 1.31 [0.86,
1.99]
4.2% (121) 2.9% (117) 1.47 [1.14,
1.89]
MACE* 10.9% (71) 8.1% (56) 1.35 [0.95,
1.92]
7.1% (202) 5.8% (232) 1.24 [1.03,
1.50]
MACE2** 7.3% (48) 5.6% (39) 1.31 [0.86,
1.99]
4.4% (127) 2.9% (119) 1.52 [1.18,
1.95]
*MACE ¼ cardiac death, MI, or clinically driven TLR; **MACE2 ¼ cardiac death, MI, or deﬁ-
nite/probable ST
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Background: Premature discontinuation of antiplatelet therapy after percutaneous
coronary intervention is known to predict stent thrombosis (ST). We aimed to
compare the impact of early versus late antiplatelet therapy discontinuation on ST in
patients receiving ﬁrst- and second-generation drug-eluting stents (DES).
Methods: A total of 6587 patients undergoing PCI with DES were analyzed, of which
4580 received 1st-generation DES (Cypher or Taxus) and 2007 received 2nd-gener-
ation DES (Xience or Promus). Patients were categorized into timing of clopidogrel
discontinuation within 1 year (never, <3 months, 3-12 months). The 1-year ARC-
deﬁned deﬁnite or probable ST was analyzed.
Results: In patients with 1st-generation DES, 536 (11.7%) had clopidogrel dis-
continued, 173 (3.8%) within ﬁrst 3 months and 363 (7.9%) at 3-12 months.
Cumulative 1-year ST rates were 1.0%, 13.6%, 3.0% (p <0.001) for never,
<3 months, 3-12 months discontinued, respectively. (Figure A) In patients with 2nd-
generation DES, 214 (11.9%) had clopidogrel discontinued, 94 (4.7%) within ﬁrst
3 months and 120 (5.9%) at 3-12 months. Cumulative 1-year ST rates were 0.1%,
5.4%, 0% (p <0.001) for never, <3 months, 3-12 months discontinued, respectively.
(Figure B).
Conclusions: Early clopidogrel discontinuation signiﬁcantly increases the risk of ST
after percutaneous coronary intervention in both 1st- and 2nd-generation DES. The
impact of clopidogrel discontinuation on ST appears to attenuate with the use of 2nd-
generation DES.TCT-8
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Background:While newer drug eluting stent (DES) promote more favorable vascular
healing, the optimal duration of dual antiplatelet therapy (DAPT) after implantation
with 2nd generation drug-eluting coronary stents remains undetermined. We aimed to
test whether 6-month DAPT would be non-inferior clinical and angiographic outcome
to 12-month DAPT after implantation of Zotarolimus-eluting stent (ZES) and
biolimus-eluting stent (BES).
Methods: This is a prospective, double-randomized, open-label, multicenter trial to
compare clinical events between 6-month DAPT and 12-month DAPT (in a 1:1 ratio),
and to demonstrate the non-inferiority of BES compared with ZES stents (in 1:1 ratio),
angiographically. Currently, 1055 patients were randomly assigned. The primary end
point was a major adverse cardiac events (MACE) at 12 months. Optical coherence
tomography (OCT) at 6 month was performed in 30 patients of each group. The
primary endpoint was MACE, secondary end points are target lesion failure, in-
segment LL at 12 months, and neointimal hyperplasia (NIH) by OCT at 6 month.acts/ORAL/Antiplatelet Agents B3
